Oral Zemplar NDA Submission, Hectorol Launch Heat Up Pre-Dialysis Market
This article was originally published in Pharmaceutical Approvals Monthly
Expanding the use of vitamin D analogs to earlier-stage chronic kidney disease patients will be a frequent topic of promotional activity in coming months, as Abbott prepares the market for its recently filed oral formulation of Zemplar and Bone Care International begins launch of a new version of Hectorol.
You may also be interested in...
User Fee Goals For Recently Announced NDA/BLA Submissions
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011